SecBot SecBot

JSPR

Jasper Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001788028 Biotech & Drug Discovery
$0.5099 −0.00 (−0.02%)
Oct 26 4:00 PM ET · prev $0.5100
Market cap
$16.5M
Nano cap
Consensus
Buy
80% Buy or better · 10 analysts
Median target
$20.00
+3822% · range $20.00–20.00
Next earnings
Nov 9
in 14 days
1 year
−78.1%
from $2.33 · Oct 27
30 days
−18.5%
from $0.6260
52-week range
$0.3410–2.36
−78% from high · low Jun 26
Avg volume 20D
373.7K
shares / day
Short interest
6.22M
≈18.7% of shares · +7.1%
Days to cover
16.3
at average volume
Insider net
$0.00
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BEARISH 10 reports · 90 days
Balance 3 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 9/10 ·Next Earnings date, Nov 9, 2026
Strongest BEARISH Jasper Therapeutics announced completion of enrollment in the IgAN cohort of its Phase 2 basket study for…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    No open-market sales.

  • InstitutionsBEARISH

    Q2 2026: 4 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    8 of 10 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +7.1% to 6.22M shares. 16.3 days to cover, ≈18.7% of shares.

  • TrendDOWNTREND

    18% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYAL BANK OF CANADATRIM40—
MILLENNIUM MANAGEMENT LLCTRIM486,933$205.0K
RENAISSANCE TECHNOLOGIES LLCADD237,900$100.2K
BlackRock, Inc.TRIM169,627$71.4K
JANE STREET GROUP, LLCDOUBLED101,743$42.8K
UBS Group AGTRIM58,759$24.7K
Jain Global LLCDOUBLED51,185$21.5K
GROUP ONE TRADING LLCDOUBLED19,930$8.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 80% rate it Buy or better
Strong Buy2Buy6Hold2Sell0Strong Sell0
12-month targets · 1 analysts

Price is below the lowest target. Median implies +3822%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 12, 2026Piper Sandler
INITIATE
INITIATEOverweight
May 15, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
May 15, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform

Insider ledger

Form 4
$0
bought · 2 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Jul 31, 2026
EMSTER KURT VON
Director
AWARD7,500 sh
Jul 31, 2026
Crutcher Patrick J
Director
AWARD7,500 sh
Jul 31, 2026
Shizuru Judith Anne
Director
AWARD7,500 sh
Jul 31, 2026
WIGGANS THOMAS G
Director
AWARD7,500 sh
Jul 31, 2026
Lucas Svetlana
Director
AWARD7,500 sh
Jul 20, 2026
Crutcher Patrick J
Director
BUY888 sh
Jul 20, 2026
Ros Matthew E
Chief Operating Officer
BUY881 sh
Jul 16, 2026
Crutcher Patrick J
Director
AWARD15,000 sh

Earnings setup

Estimates
Nov 9
reports in 14 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$0.23-$0.41–-$0.05—$6.0M
Next FY-$0.70-$1.31–-$0.10—$0.00

Short side

FINRA· Sep 30, 2026
6,218,239
shares short
+7.1%
vs prior settlement
16.3
days to cover
≈18.7%
of shares outstanding
Trading halts
Jul 16, 2026Resumption ScheduledNot resumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
Jasper Therapeutics is amending its issuer tender offer to repurchase any and all of its 12,345,707 outstanding…
SC TO-I/A — Impact 4/10
Oct 20, 2026 SEC
Jasper Therapeutics is holding a special meeting on November 13, 2026, to seek stockholder approval for the issuance…
DEF 14A — Impact 5/10
Oct 15, 2026 SEC
Jasper Therapeutics completed enrollment of the IgA nephropathy (IgAN) cohort in its Phase 2 basket study of…
8-K — Impact 3/10
Oct 15, 2026 Press
Jasper Therapeutics announced completion of enrollment in the IgAN cohort of its Phase 2 basket study for vensobafusp…
Impact 7/10
Oct 15, 2026 FDA
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansi
Jul 31, 2026 Insider
EMSTER KURT VON was granted 7,500 shares
Director
Jul 31, 2026 Insider
Crutcher Patrick J was granted 7,500 shares
Director
Jul 31, 2026 Insider
Shizuru Judith Anne was granted 7,500 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
JSPR Q3 2026 Earnings Before Market Open — 2026-11-09
Recent
Oct 15, 2026
FDA
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort in patients with FSGS, with first…
Sep 15, 2026
Press release
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs
Sep 8, 2026
Trial readout
Results Pending: Briquilimab (Phase 2) — Completed 62d ago
Trial: Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With…
Sep 8, 2026
Trial readout
Results Pending: Briquilimab (Phase 2) — Completed 62d ago
Trial: Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With…
Aug 25, 2026
Trial readout
Results Pending: Briquilimab (Phase 2) — Completed 48d ago
Trial: Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With…

SecBot reports

13 filings · 3 press releases · 1 bullish · 2 bearish · 1 mixed · 9 neutral
All JSPR filing & press-release reports (16)